Evidence Question
What does direct evidence report when dulaglutide dose escalation is compared with tirzepatide for incidence of gastrointestinal disorders?
Related to: Adverse Events and SafetyShort answer
In indexed direct evidence at the reported timepoint, no difference was reported for incidence of gastrointestinal disorders.
Why do we say this?
The available direct comparison reported no difference for this outcome at the reported timepoint, but the head-to-head evidence base is limited.
Explore the evidence
Related questions
- What does direct evidence report when dulaglutide dose escalation is compared with tirzepatide for severe hypoglycemia?
- What adverse-event evidence has been reported for tirzepatide and incidence of gastrointestinal disorders?
- What adverse-event evidence has been reported for dulaglutide dose escalation and incidence of gastrointestinal disorders?